Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

This study is testing a flavored, liquid oral form of irinotecan (brand name Orotecan) given together with temozolomide — both cancer medicines — for children and young adults with solid tumors or brain tumors that have come back after prior treatment. The study is looking at whether this easier-to-swallow oral version is safe and practical. **You may be eligible if...** - You are between 1 and 30 years old - You have a solid tumor or brain tumor confirmed by biopsy (either at original diagnosis or at relapse) - Your cancer has come back and there is no known cure or effective standard treatment remaining - You are physically active enough to do basic activities (Karnofsky/Lansky score of at least 50) - You have recovered from side effects of prior treatments - You agree to use effective contraception if of reproductive age **You may NOT be eligible if...** - Your cancer progressed while you were actively on irinotecan or temozolomide - You are still experiencing significant side effects from your last treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.